NAGE
Niagen Bioscience Inc.

3,541
Mkt Cap
$409.21M
Volume
78.00
52W High
$14.69
52W Low
$4.73
PE Ratio
24.99
NAGE Fundamentals
Price
$5.22
Prev Close
$5.11
Open
$5.12
50D MA
$5.75
Beta
1.34
Avg. Volume
952,281.20
EPS (Annual)
$0.2034
P/B
5.32
Rev/Employee
$1.11M
$481.40
Loading...
Loading...
News
all
press releases
Niagen Bioscience Launches Niagen Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud, From Tru Niagen Powered by Patented Niagen
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Niagen Skincare...
Business Wire·20h ago
News Placeholder
More News
News Placeholder
HC Wainwright Issues Optimistic Outlook for NAGE Earnings
Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - HC Wainwright increased their Q1 2026 earnings estimates for shares of Niagen Bioscience in a report released on Thursday, March 5th. HC...
MarketBeat·5d ago
News Placeholder
Canaccord Genuity Group Cuts Niagen Bioscience (NASDAQ:NAGE) Price Target to $13.00
Canaccord Genuity Group dropped their price objective on Niagen Bioscience from $14.00 to $13.00 and set a "buy" rating for the company in a report on Thursday...
MarketBeat·5d ago
News Placeholder
Niagen Bioscience Rallies 18% After Hours: Here's Why
Niagen Bioscience Inc. surged in after-hours trading after reporting record 2025 results, while maintaining a cautious outlook for 2026.read more...
Benzinga·6d ago
News Placeholder
Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion Stock Jumps After-Hours (UPDATED)
NAD+ company Niagen Bioscience doubles profits in 2025, eyes acquisitions and new markets as the longevity market picks up momentum.read more...
Benzinga·6d ago
News Placeholder
Niagen Bioscience (NAGE) Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·6d ago
News Placeholder
Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +100.00% and +8.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results. Fourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter Total net...
Business Wire·6d ago
News Placeholder
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone PR Newswire NEW YORK...
PR Newswire·8d ago
News Placeholder
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex...
Business Wire·13d ago
<
1
2
...
>

Latest NAGE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.